Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124313 | 0.95 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17527387 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL18419032 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20183474 | 0.83 | ALOX5AP (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGSCN9A | |
| SCHEMBL21632467 | 0.81 | GPR119 (0.46) | GPR119PIK3CD | |
| SCHEMBL27028318 | 0.80 | JAK1 (0.43) | GPR119PIK3CDKCNH2 | |
| SCHEMBL29983203 | 0.80 | JAK1 (0.43) | GPR119PIK3CDKCNH2 | |
| SCHEMBL21632536 | 0.79 | FAAH (0.44) | GPR119 | |
| SCHEMBL17466963 | 0.78 | PIK3CD (0.36) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL22553710 | 0.78 | ACHE (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | GPR119 684/4885PIK3CD 672/4885PIK3CA 367/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | GPR119 1259/4885PIK3CD 311/4885PIK3CA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.